TherapeuticsMD reports 2025 full-year net loss of $0.7M, license revenue up 71.6% to $3.0M

TherapeuticsMD, Inc.

Net loss from continuing operations narrowed to $0.7M ($0.06 per share) from $2.3M in 2024.
License revenue rose 71.6% to $3.0M, primarily driven by the Mayne License Agreement.
Total operating expenses decreased 5.9% to $7.4M, partly due to lower impairment charges.
Cash and cash equivalents stood at $7.5M as of December 31, 2025.
Company continues to evaluate strategic alternatives including M&A or sale of assets.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TherapeuticsMD, Inc. reported the full year ended December 31, 2025 results: revenue $3.0 million, net income $(0.7) million, EPS $(0.06) per basic and diluted common share.

Period: the full year ended December 31, 2025
Revenue: $3.0 million
Net income: $(0.7) million
EPS: $(0.06) per basic and diluted common share
Result: reported results

Exact text from the filing

or $(0.20) per basic and diluted common share, for 2024. License Revenues from Continuing Operations ● License revenue, primarily from the Mayne License Agreement, totaled $3.0 million during the year ended December 31, 2025, an increase of $1.3 million, or 71.6%, compared to $1.8 million in license revenue during the year ended December 31, 2024. The increase

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-036519

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.